Kymera’s STAT6 degrader breaks ahead of competition: BioCentury’s Clinical Report 

An oral STAT6 degrader from Kymera has overcome its first clinical hurdle in healthy volunteers, showing that potent depletion of the once undruggable inflammatory disease target is possible with a targeted protein degrader. As a result, the oral small molecule advances ahead of other STAT6 degraders at the center of recent pharma deals. 

In a first-in-human study, the molecule from Kymera Therapeutics Inc. (NASDAQ:KYMR), KT-621, led to STAT6 degradation in both blood and skin. Mean blood STAT6 degradation reached >90% across all single doses, with the highest doses reaching >95% degradation by four hours. Within the multiple-ascending dose arm, mean STAT6 skin degradation reached >95% — a level defined by the company as “complete degradation” — by day 7 for daily higher doses...